Lyell Immunopharma (LYEL) Gains from Investment Securities (2020 - 2024)

Lyell Immunopharma (LYEL) has 5 years of Gains from Investment Securities data on file, last reported at -$13.0 million in Q4 2024.

• For the quarter ending Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$13.0 million; the trailing twelve-month figure through Sep 2024 stood at $13.0 million (up 44.62% YoY), and the FY2023 full-year result was $12.9 million, up 1111.15% from the prior year.
• Gains from Investment Securities eased to -$13.0 million in Q4 2024, from $13.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $36.4 million in Q4 2021 to a low of -$13.0 million in Q4 2024.
• A 5-year average of $4.2 million and a median of $78500.0 in 2021 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities soared 130100.0% in 2021 and slumped 110.8% in 2022, its largest moves.
• Tracing LYEL's Gains from Investment Securities over 5 years: stood at -$28000.0 in 2020, then soared by 130100.0% to $36.4 million in 2021, then tumbled by 110.8% to -$3.9 million in 2022, then jumped by 174.32% to $2.9 million in 2023, then tumbled by 544.78% to -$13.0 million in 2024.
• Business Quant data shows LYEL's Gains from Investment Securities at -$13.0 million in Q4 2024, $13.0 million in Q1 2024, and $2.9 million in Q2 2023.